Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

30%

3 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

N/A

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 3(2)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT01659411Completed

Adult Congenital Heart Disease Registry (QuERI)

Role: collaborator

NCT01623492Completed

Eisenmenger Quality Enhancement Research Initiative

Role: collaborator

NCT03994575Completed

North American Acute Coronary Syndrome (ACS) Reflective III Pilot

Role: lead

NCT02537535Completed

Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada

Role: lead

NCT01389206Completed

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Role: collaborator

NCT00518245Phase 4Terminated

Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)

Role: lead

NCT00131664Phase 3Completed

Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)

Role: lead

NCT00164190Not ApplicableCompleted

Routine Angioplasty and Stenting After Fibrinolysis for Acute Myocardial Infarction

Role: lead

NCT00517257Phase 3Unknown

Atorvastatin for the Treatment of Retinal Vein Occlusion

Role: collaborator

NCT00408057Completed

Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE )

Role: lead

All 10 trials loaded